Brief: Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
21/08/2024 14:02
Aug 21 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA THERAPEUTICS AND QUANTUM LEAP HEALTHCARE
COLLABORATIVE
DOSE FIRST PATIENT IN I-SPY 2 TRIAL COMBINING (Z)-ENDOXIFEN WITH
ABEMACICLIB FOR ER+/HER2- BREAST CANCER
* ATOSSA THERAPEUTICS: DATA FROM STUDY ANTICIPATED IN 2026
Source text for Eikon: ID:nGNX3Dl4Jh
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary